MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

MDT

99.5

-0.24%↓

147.28

+1.07%↑

VEEV

244.14

+1.84%↑

HQY

97.26

0%↓

PHR.US

17.07

-2.68%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

552.93 -1.06

Buy Sell

Overview

Share price change

24h

Current

Min

550.1

Max

584.95

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+11.6% upside

Market Stats
By TradingEconomics
Market Cap	4.2B 13B
Previous open	553.99
Previous close	552.93

News Sentiment

By Acuity

11%

89%

9 / 372 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 sty 2026, 23:11 UTC

Earnings

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7 sty 2026, 22:55 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7 sty 2026, 21:39 UTC

Major Market Movers

Raytheon Down Following Trump Post Criticizing Company

7 sty 2026, 20:13 UTC

Major Market Movers

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7 sty 2026, 20:03 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7 sty 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 sty 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7 sty 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7 sty 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7 sty 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7 sty 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7 sty 2026, 22:46 UTC

Earnings

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7 sty 2026, 22:45 UTC

Earnings

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7 sty 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Revolution Medicines Draws Takeover Interest -- 2nd Update

7 sty 2026, 22:42 UTC

Earnings

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7 sty 2026, 22:41 UTC

Earnings

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7 sty 2026, 22:40 UTC

Major Market Movers

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7 sty 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7 sty 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7 sty 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 sty 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7 sty 2026, 21:22 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7 sty 2026, 21:18 UTC

Acquisitions, Mergers, Takeovers

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7 sty 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7 sty 2026, 20:29 UTC

Acquisitions, Mergers, Takeovers

AbbVie Near Deal for Revolution Medicines -- Update

7 sty 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7 sty 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7 sty 2026, 19:48 UTC

Major Market Movers

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

11.6% upside

12 Months Forecast

Average 626.22 USD 11.6%

High 900 USD

Low 527 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

9 / 372 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.